Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record.

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy

Open access
McAuliffe, Shannon M., Morgan, Stefanie L., Wyant, Gregory A., Tran, Lieu T., Muto, Katherine W., Chen, Yu Sarah, Chin, Kenneth T., Partridge, Justin C., Poole, Barish B., Cheng, Kuang-Hung, Daggett, John, Cullen, Kristen, Kantoff, Emily, Hasselbatt, Kathleen, Berkowitz, Julia, Muto, Michael G., Berkowitz, Ross S., Aster, Jon C., Matulonis, Ursula A., Dinulescu, Daniela M.·2012·Proceedings of the National Academy of Sciences

Abstract

Chemoresistance to platinum therapy is a major obstacle that needs to be overcome in the treatment of ovarian cancer patients. The high rates and patterns of therapeutic failure seen in patients are consistent with a steady accumulation of drug-resistant cancer stem cells (CSCs). This study demonstrates that the Notch signaling pathway and Notch3 in particular are critical for the regulation of CSCs and tumor resistance to platinum. We show that Notch3 overexpression in tumor cells results in expansion of CSCs and increased platinum chemoresistance. In contrast, γ-secretase inhibitor (GSI), a Notch pathway inhibitor, depletes CSCs and increases tumor sensitivity to platinum. Similarly, a Notch3 siRNA knockdown increases the response to platinum therapy, further demonstrating that modulation of tumor chemosensitivity by GSI is Notch specific. Most importantly, the cisplatin/GSI combination is the only treatment that effectively eliminates both CSCs and the bulk of tumor cells, indicating that a dual combination targeting both populations is needed for tumor eradication. In addition, we found that the cisplatin/GSI combination therapy has a synergistic cytotoxic effect in Notch-dependent tumor cells by enhancing the DNA-damage response, G 2 /M cell-cycle arrest, and apoptosis. Based on these results, we conclude that targeting the Notch pathway could significantly increase tumor sensitivity to platinum therapy. Our study suggests important clinical applications for targeting Notch as part of novel treatment strategies upon diagnosis of ovarian cancer and at recurrence. Both platinum-resistant and platinum-sensitive relapses may benefit from such an approach as clinical data suggest that all relapses after platinum therapy are increasingly platinum resistant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1206400109

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 328

Metadata

Authors
McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., Daggett, J., Cullen, K., Kantoff, E., Hasselbatt, K., Berkowitz, J., Muto, M. G., Berkowitz, R. S., Aster, J. C., Matulonis, U. A., & Dinulescu, D. M.
Venue
Proceedings of the National Academy of Sciences
Published
2012-09-27
Volume
109
Issue
43
Pages
E2939-48
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2107400278
Cited by
328
References
0
FWCI
15.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. https://app.cochat.ai/papers/10.1073/pnas.1206400109
The paper
McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., Daggett, J., Cullen, K., Kantoff, E., Hasselbatt, K., Berkowitz, J., Muto, M. G., Berkowitz, R. S., Aster, J. C., Matulonis, U. A., & Dinulescu, D. M. (2012). Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1206400109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.